March 16, 2016 / 4:08 PM / 2 years ago

BRIEF-S&P places Valeant Pharmaceuticals' 'B+' rating on CreditWatch Negative

March 16 (Reuters) - S&P:

* Valeant Pharmaceuticals International Inc. ‘B+’ rating placed on CreditWatch Negative

* Although Valeant states it will be able to meet financial covenants through 2016, the cushion on these covenants is diminishing

* We expect Valeant to succeed with obtaining waivers to resolve covenants in its credit agreement

* Potential for further operational deterioration due to loss of employees or diminished negotiating power with partners now that Co is weakened

* “The delay in filing its 10-K for 2015 will likely result in a violation of reporting covenants this month”

* If Valeant's performance falls short of current expectations the company could be forced to pursue a covenant waiver or asset sales Source text - bit.ly/1ROfCyp Further company coverage: [VRX.TO VRX.N]

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below